What is IRB?
IRB
The IRB (Institutional Review Board) is the ethics-review body that must approve research involving human subjects before it can proceed. The material tracks criticism of how IRBs function in practice, particularly their vulnerability to single-objection vetoes and the layered, overlapping review processes surrounding them.
How it developed
- Jun 2026 - An unnamed speaker said that clearing the IRB at MD Anderson was, from one figure’s perspective, sufficient validation, and should likewise satisfy the Fred Hutch.
- Aug 2026 - Nathan Grubaugh said IRB review is “extremely vulnerable to the heckler’s veto,” noting that one uncomfortable person can prevent a study from ever proceeding.
- Aug 2026 - A BioCentury This Week host described IRBs, review boards, and scientific councils as largely overlapping “Byzantine” processes that do not necessarily add value or rigor at each stage.
In the evidence
Every line below is attributed to a named speaker.
IRB consent requirements for environmental intervention trials create a structural 'heckler's veto' that may make randomized controlled trials of far-UVC effectively impossible to conduct
“That is extremely vulnerable to the heckler's veto. You just need one person who is just not totally comfortable with it and the IRB will never let you do it.”Nathan Grubaugh · 16 Aug 2026
Nathan Grubaugh on IRB research being vulnerable to a single dissenting participant
“That is extremely vulnerable to the heckler's veto. You just need one person who is just not totally comfortable with it and the IRB will never let you do it.”Nathan Grubaugh · 16 Aug 2026
Overlapping IRB, review board, and scientific council processes add neither incremental value nor extra rigor at each stage of the drug development chain, functioning instead as redundant bureaucratic layers.
“There's a lot of, sort of, Byzantine, as it were, kind of processes, IRBs and review boards and scientific councils, and all of these are largely overlapping and really not necessarily adding value at each stage of the chain or even extra rigor.”BioCentury This Week Host · 28 Aug 2026
Mutual recognition of IRB approvals across NCI-designated cancer centers (such that MD Anderson approval covers Fred Hutch) could eliminate a major layer of redundant review, but is not current practice.
“If you get through the IRB at MD Anderson, from his perspective, that's good enough for him. That should be good enough for the Fred Hutch.”<UNKNOWN> · 11 Jun 2026